Clinical Trial: 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID)
What is the LUMOD-ID trial? This is a randomized controlled clinical trial evaluating the impact of forward planning dosimetry for Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals), a radiopharmaceutical approved to treat neuroendocrine tumors by the U.S. FDA. The primary outcome measure is to determine objective response rate in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) treated with dosimetrically-determined LUTATHERA administration compared to active control. This is done at 6 months after treatment completion along with a secondary outcome correlation of hematologic toxicities every 6 months for 5 years. The remaining secondary outcome measures are after 5 years to…
